CD4 and neoplasm: Compared with controls, mice receiving antiOX40 monotherapy exhibited improved survival; Coadministration of antiOX40 and antiPD-1 led to Treg depletion concurrent with an expansion in CD4+ and CD8+ T cell populations, resulting in complete tumor eradication (48).